Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type i IGF receptor

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 117-126

  Zeng, Xianke ^a,b   Zhang, Hua ^a,c   Oh, Annabell ^a   Zhang, Yan ^a   Yee, Douglas ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Autophagy; Doxorubicin; Insulin; Insulin like growth factors; Tyrosine kinase inhibitor

Indexed keywords

CIS 3 [3 (4 METHYL PIPERAZIN 1 YL)CYCLOBUTYL] 1 (2 PHENYL QUINOLIN 7 YL) IMIDAZO[1,5 A]PYRAZIN 8 YLAMINE; DOXORUBICIN; INSULIN RECEPTOR KINASE; LINSITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER INHIBITION; CELL STRAIN; CELL STRAIN LCC6; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOLAYER CULTURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; PYRAZINES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860339842     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1713-x     Document Type: Article

References (43)

1. MD Pegram R Pietras A Bajamonde P Klein G Fyfe 2005 Targeted therapy: wave of the future J Clin Oncol 23 8 1776 1781 15755985 10.1200/JCO.2005.11.029 1:CAS:528:DC%2BD2MXjtVCqu78%3D (Pubitemid 46211429)
2. RH Alvarez V Valero GN Hortobagyi 2010 Emerging targeted therapies for breast cancer J Clin Oncol 28 20 3366 3379 20530283 10.1200/JCO.2009.25.4011 1:CAS:528:DC%2BC3cXhtVajurvF
3. M Pollak 2008 Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 12 915 928 19029956 10.1038/nrc2536 1:CAS:528:DC%2BD1cXhsVWhu7rL
4. D Sachdev 2008 Regulation of breast cancer metastasis by IGF signaling J Mammary Gland Biol Neoplasia 13 4 431 441 19030970 10.1007/s10911-008-9105-5
5. L Sepp-Lorenzino 1998 Structure and function of the insulin-like growth factor I receptor Breast Cancer Res Treat 47 3 235 253 9516079 10.1023/A:1005955017615 1:CAS:528:DyaK1cXit1Kjtb0%3D (Pubitemid 28059820)
6. EM Bailyes BT Nave MA Soos SR Orr AC Hayward K Siddle 1997 Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting Biochem J 327 1 209 215 9355755 1:CAS:528:DyaK2sXmvVGktrw%3D (Pubitemid 27455481)
7. D Sachdev D Yee 2001 The IGF system and breast cancer Endocr Relat Cancer 8 3 197 209 11566611 10.1677/erc.0.0080197 1:CAS:528:DC%2BD3MXotlCqsLk%3D (Pubitemid 32947642)
8. SJ Weroha P Haluska 2008 IGF-1 receptor inhibitors in clinical trials-early lessons J Mammary Gland Biol Neoplasia 13 4 471 483 19023648 10.1007/s10911-008-9104-6
9. M Hewish I Chau D Cunningham 2009 Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine Recent Pat Anticancer Drug Discov 4 1 54 72 19149688 10.2174/157489209787002515 1:CAS:528:DC%2BD1MXkslClt7c%3D
10. QS Ji MJ Mulvihill M Rosenfeld-Franklin A Cooke L Feng G Mak M O'Connor Y Yao C Pirritt E Buck, et al. 2007 A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo Mol Cancer Ther 6 8 2158 2167 17671083 10.1158/1535-7163.MCT-07-0070 1:CAS:528:DC%2BD2sXptVGltLg%3D (Pubitemid 47294744)
11. MJ Mulvihill A Cooke M Rosenfeld-Franklin E Buck K Foreman D Landfair M O'Connor C Pirritt Y Sun Y Yao, et al. 2009 Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor Future Med Chem 1 6 1153 1171 21425998 10.4155/fmc.09.89 1:CAS:528: DC%2BD1MXhsVChs7zM
12. A Hopkins PJ Crowe JL Yang 2010 Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved J Cancer Res Clin Oncol 136 5 639 650 20140624 10.1007/s00432-010-0792-0 1:CAS:528:DC%2BC3cXjs1ejtbg%3D
13. LJ Pierce LF Hutchins SR Green DL Lew JR Gralow RB Livingston CK Osborne KS Albain 2005 Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer J Clin Oncol 23 1 24 29 15545669 10.1200/JCO.2005.01.198 1:CAS:528:DC%2BD2MXpslalug%3D%3D (Pubitemid 41702620)
14. S Abuharbeid J Apel G Zugmaier C Knabbe M Sander S Gilbert F Czubayko A Aigner 2005 Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells Naunyn Schmiedebergs Arch Pharmacol 371 2 141 151 15700118 10.1007/s00210-004-1016-4 1:CAS:528:DC%2BD2MXisV2iu70%3D (Pubitemid 40487419)
15. X Zeng D Sachdev H Zhang M Gaillard-Kelly D Yee 2009 Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo Clin Cancer Res 15 8 2840 2849 19351773 10.1158/1078-0432. CCR-08-1401 1:CAS:528:DC%2BD1MXksV2ntrg%3D
16. D Sachdev JS Hartell AV Lee X Zhang D Yee 2004 A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells J Biol Chem 279 6 5017 5024 14615489 10.1074/jbc.M305403200 1:CAS:528: DC%2BD2cXpslSitw%3D%3D (Pubitemid 38199098)
17. Verbeke G, Molenberghs G (2000) Linear mixed models for longitudinal data. In
18. KJ Cullen D Yee WS Sly J Perdue B Hampton ME Lippman N Rosen 1990 Insulin-like growth factor receptor expression and function in human breast cancer Cancer Res 50 1 48 53 2152773 1:CAS:528:DyaK3cXhtlKlurk%3D (Pubitemid 20029992)
19. AF Chambers 2009 MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69 13 5292 5293 19549886 10.1158/0008-5472.CAN-09-1528 1:CAS:528:DC%2BD1MXnvFWqurg%3D
20. JM Rae CJ Creighton JM Meck BR Haddad MD Johnson 2007 MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research Breast Cancer Res Treat 104 1 13 19 17004106 10.1007/s10549-006-9392-8 (Pubitemid 46976633)
21. F Leonessa D Green T Licht A Wright K Wingate-Legette J Lippman MM Gottesman R Clarke 1996 MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer Br J Cancer 73 2 154 161 8546900 10.1038/bjc.1996.29 1:STN:280:DyaK287ltVWgtA%3D%3D
22. H Zhang DH Fagan X Zeng KT Freeman D Sachdev D Yee 2010 Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation Oncogene 29 17 2517 2527 20154728 10.1038/onc.2010.17 1:CAS:528: DC%2BC3cXhs1Olu7k%3D
23. D Sachdev X Zhang I Matise M Gaillard-Kelly D Yee 2010 The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival Oncogene 29 2 251 262 19838209 10.1038/onc.2009.316 1:CAS:528:DC%2BD1MXht1Ogsr%2FL
24. CH Jung CB Jun SH Ro YM Kim NM Otto J Cao DH Kim M Kundu 2009 ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery Mol Biol Cell 20 7 1992 2003 19225151 10.1091/mbc.E08-12-1249 1:CAS:528: DC%2BD1MXotVyqsL8%3D
25. N Mizushima T Yoshimori 2007 How to interpret LC3 immunoblotting Autophagy 3 6 542 545 17611390 1:CAS:528:DC%2BD2sXhtlOhs7jL (Pubitemid 350060049)
26. AE Wahner Hendrickson P Haluska PA Schneider DA Loegering KL Peterson R Attar BD Smith C Erlichman M Gottardis JE Karp, et al. 2009 Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro Cancer Res 69 19 7635 7643 19789352 10.1158/0008-5472.CAN-09-0511 1:CAS:528:DC%2BD1MXht1Skt7vL
27. YW Chen V Boyartchuk BC Lewis 2009 Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells Neoplasia 11 9 835 845 19724677 1:CAS:528:DC%2BD1MXhtVKht7vK
28. S Avnet L Sciacca M Salerno G Gancitano MF Cassarino A Longhi M Zakikhani JM Carboni M Gottardis A Giunti, et al. 2009 Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma Cancer Res 69 6 2443 2452 19258511 10.1158/0008-5472.CAN-08-2645 1:CAS:528:DC%2BD1MXjtFyqur4%3D
29. E Buck PC Gokhale S Koujak E Brown A Eyzaguirre N Tao M Rosenfeld-Franklin L Lerner MI Chiu R Wild, et al. 2010 Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer Mol Cancer Ther 9 10 2652 2664 20924128 10.1158/1535-7163.MCT-10-0318 1:CAS:528:DC%2BC3cXht1Khtr3E
30. DB Ulanet DL Ludwig CR Kahn D Hanahan 2010 Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy Proc Natl Acad Sci USA 107 24 10791 10798 20457905 10.1073/pnas.0914076107 1:CAS:528:DC%2BC3cXotVKqtb0%3D
31. RC Wang B Levine 2010 Autophagy in cellular growth control FEBS Lett 584 7 1417 1426 20096689 10.1016/j.febslet.2010.01.009 1:CAS:528: DC%2BC3cXjs12msrY%3D
32. J Pimkina ME Murphy 2009 ARF, autophagy and tumor suppression Autophagy 5 3 397 399 19221462 10.4161/auto.5.3.7782 1:CAS:528:DC%2BD1MXnvVyrsrc%3D
33. B Levine G Kroemer 2008 Autophagy in the pathogenesis of disease Cell 132 1 27 42 18191218 10.1016/j.cell.2007.12.018 1:CAS:528:DC%2BD1cXhtFehtb8%3D
34. X Li Z Fan 2010 The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex Cancer Res 70 14 5942 5952 20634405 10.1158/0008-5472.CAN-10-0157 1:CAS:528:DC%2BC3cXovVanu7k%3D
35. XF Le W Mao Z Lu BZ Carter RC Bast Jr 2010 Dasatinib induces autophagic cell death in human ovarian cancer Cancer 116 21 4980 4990 20629079 10.1002/cncr.25426 1:CAS:528:DC%2BC3cXhsVymtL%2FN
36. A Ullen M Farnebo L Thyrell S Mahmoudi P Kharaziha L Lennartsson D Grander T Panaretakis S Nilsson 2010 Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro Int J Oncol 37 1 15 20 20514392 10.3892/ijo-00000648 1:CAS:528:DC%2BC3cXpsVGqsLo%3D
37. N Osheroff AH Corbett MJ Robinson 1994 Mechanism of action of topoisomerase II-targeted antineoplastic drugs Adv Pharmacol 29B 105 126 8996604 10.1016/S1054-3589(08)61134-5 1:CAS:528:DyaK2MXjsVais7g%3D
38. SA Flanigan TM Pitts SG Eckhardt JJ Tentler AC Tan A Thorburn S Leong 2010 The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models Clin Cancer Res 16 22 5436 5446 20943761 10.1158/1078-0432.CCR-10-2054 1:CAS:528:DC%2BC3cXhsVWmsbjN
39. R Vasilcanu D Vasilcanu L Rosengren N Natalishvili B Sehat S Yin A Girnita M Axelson L Girnita O Larsson 2008 Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1 Oncogene 27 11 1629 1638 17828296 10.1038/sj.onc.1210797 1:CAS:528:DC%2BD1cXivFyrsb4%3D (Pubitemid 351347881)
40. CK Carden ES Kim R Jones S Alam F Johnson A Stephens S Poondru R Gedrich S Lippman S Kaye 2010 Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors J Clin Oncol 18 2530
41. R Novosyadlyy DE Lann A Vijayakumar A Rowzee DA Lazzarino Y Fierz JM Carboni MM Gottardis PA Pennisi AA Molinolo, et al. 2010 Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes Cancer Res 70 2 741 751 20068149 10.1158/0008-5472.CAN-09-2141 1:CAS:528:DC%2BC3cXltlajsQ%3D%3D
42. DD Karp LG Paz-Ares S Novello P Haluska L Garland F Cardenal LJ Blakely PD Eisenberg CJ Langer G Blumenschein Jr, et al. 2009 Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 15 2516 2522 19380445 10.1200/JCO.2008.19.9331 1:CAS:528:DC%2BD1MXmvVOhsb4%3D
43. P Haluska HM Shaw GN Batzel D Yin JR Molina LR Molife TA Yap ML Roberts A Sharma A Gualberto, et al. 2007 Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors Clin Cancer Res 13 19 5834 5840 17908976 10.1158/1078-0432.CCR-07-1118 1:CAS:528:DC%2BD2sXhtFSntLrE (Pubitemid 47583908)